CTOs on the Move

Eli Lilly

www.lilly.com

 
Lilly makes medicines that help people live longer, healthier, more active lives. We were founded by Eli Lilly in 1876, and are now the 10th largest pharmaceutical company in the world. We have steadfastly remained independent, but not isolated. Across the globe, Lilly has developed productive alliances and partnerships that advance our capacity to develop innovative medicines at lower costs. Lilly is consistently ranked as one of the best companies in the world to work for, and generations of Lilly employees have sustained a culture that values excellence, integrity, and respect for people. We make medicines that help people live longer, ...
  • Number of Employees: 5K-10K
  • Annual Revenue: > $1 Billion
  • www.lilly.com
  • 1 Lilly Corporate Ctr
    Indianapolis, IN USA 46285
  • Phone: 317.276.2000

Executives

Name Title Contact Details
Mike Boland
 Sr. Director - Counsel - eDiscovery and Information Management Profile
Francisco Toste
 VP Supply Chain Design and Transformation Profile
Charlie Haddad
 VP - Chief Enterprise Business Architect Profile
Nick Merker
 Associate Vice-President, Assistant General Counsel, AI, Information Security and Privacy Profile
Jeff Christoffersen
 Senior Director-Information Profile

Similar Companies

Ascend Therapeutics

Ascend Therapeutics is a Herndon, VA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Interspond

Interspond is a Trial Management Organization (TMO) that works with a network of multi therapeutic sites across the country to facilitate clinical and pharmaceutical research and trials.

La Jolla Pharmaceutical Company

La Jolla Pharmaceutical Company is a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases. The Company has four product candidates in development. LJPC-501 is La Jolla’s proprietary formulation of angiotensin II for the potential treatment of catecholamine-resistant hypotension and hepatorenal syndrome. GCS-100 is La Jolla’s first-in-class galectin-3 inhibitor for the potential treatment of chronic kidney disease. LJPC-1010, La Jolla’s second-generation galectin-3 inhibitor, is a more potent and purified derivative of GCS-100 that can be delivered orally for the potential treatment of nonalcoholic steatohepatitis and other diseases characterized by tissue fibrosis. LJPC-401 is La Jolla’s novel formulation of hepcidin for the potential treatment of conditions characterized by iron overload, such as hemochromatosis and beta thalassemia

Circle Pharma

Circle Pharma initiated operations in June 2014 with seed funding from Pfizer, Inc. and Mission Bay Capital, LLP; we received additional seed funding from ShangPharma Investment Group Limited in November 2015.

Indago

Indago is developing smart surgical tools that enable physicians to focus on healthcare, not hardware. Our mission: to create the OR of the future.